Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's New OTC Drugs Director Ganley Brings Cardio-Renal Background To Job

This article was originally published in The Tan Sheet

Executive Summary

Charles Ganley, MD, the new director of FDA's Division of OTC Drugs, brings to the post a background as an agency medical reviewer in the Division of Cardio-Renal Drug Products, where he has worked since 1989. He will report to Office of Drug Evaluation V Director Robert DeLap, MD/PhD.
Advertisement

Related Content

OTC Division Deputy Director Katz Leaving To Head Cosmetics, Colors Office
OTC Division Deputy Director Katz Leaving To Head Cosmetics, Colors Office
OTC Division Deputy Director Katz Leaving To Head Cosmetics, Colors Office
OTC Switch Public Policy, Science Issues Workshop Proposed
OTC Switch Public Policy, Science Issues Workshop Proposed
OTC Switch Public Policy, Science Issues Workshop Proposed

Topics

Advertisement
UsernamePublicRestriction

Register

PS089925

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel